The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Glaukos Corporation GKOS recently announced the commercial availability of Epioxa, marking a significant milestone in its corneal health portfolio. The therapy stands out as the first FDA-approved, ...

Please provide your email address to receive an email when new articles are posted on . At 6 months, maximum keratometry improved by a mean of 0.5 D in eyes treated with Epioxa. Best corrected visual ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...

Glaukos (GKOS) announced the submission of its New Drug Application NDA to the U.S. Food and Drug Administration FDA or Epioxa or Epi-on, its next-generation corneal cross-linking iLink therapy for ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, ...

Please provide your email address to receive an email when new articles are posted on . Epioxa is the first epithelium-on cross-linking procedure approved in the U.S. Glaukos plans for Epioxa to be ...

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus, a Sight-Threatening Rare Disease Glaukos Corporation ...

The company reaffirmed its 2026 net sales guidance range of $600 million to $620 million, driven by iDose TR in the U.S. glaucoma segment and the launch of Epioxa in corneal health. Gilliam detailed, ...